Tagged With: Marketing

Regulators at the US Food and Drug Administration today granted market approval for Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. The FDA’s decision was not unexpected, as the proprietary extract formulation — developed by … Continue reading »